Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

SABCS 2023: Highlights

SABCS 2023

Published: 2 Jan 2024

Views: 160

Rating:

Save

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

Dr Matteo Lambertini talks to ecancer about several important presentations from SABCS 2023.

He discusses fertility preservation and assisted reproductive technologies in breast cancer patients interrupting endocrine therapy to attempt pregnancy and also talks about the results of the monarchE, INAVO120 and NATALEE trials.

Dr Lambertini further talks about other studies in the HER2-positive disease subtype and the triple-negative setting.

Related Videos

Patients with early-stage, HR+/HER2-negative BC may benefit from adjuvant T-AC...

Dr Nan Chen - The University of Chicago, Chicago, USA

Patients with early-stage, HR+/HER2-negative BC may benefit from adjuvant T-AC therapy more than from TC ( Dr Nan Chen - The University of Chicago, Chicago, USA )

Postmastectomy radiotherapy in 'intermediate-risk' breast cancer does not...

Prof Ian Kunkler - University of Edinburgh, Edinburgh, UK

Postmastectomy radiotherapy in 'intermediate-risk' breast cancer does not impact overall survival ( Prof Ian Kunkler - University of Edinburgh, Edinburgh, UK )

Guiding transplant decisions in multiple myeloma with MRD

Dr Susan Bal - University of Alabama at Birmingham, Birmingham, USA

Guiding transplant decisions in multiple myeloma with MRD ( Dr Susan Bal - University of Alabama at Birmingham, Birmingham, USA )

ESMO and WCLC: Latest developments in EGFR mutated NSCLC

Dr Matthew Krebs, Dr Antonio Passaro, Dr Enriqueta Felip and Prof Pascale...

ESMO and WCLC: Latest developments in EGFR mutated NSCLC ( Dr Matthew Krebs, Dr Antonio Passaro, Dr Enriqueta Felip and Prof Pascale Tomasini )

Understanding the use of PARPi combinations to treat patients with mCRPC

Prof Axel Merseburger, Dr Friederike Schlurmann, Dr Elena Castro and Prof...

Understanding the use of PARPi combinations to treat patients with mCRPC ( Prof Axel Merseburger, Dr Friederike Schlurmann, Dr Elena Castro and Prof Gerhardt Attard )

Durable responses in aRCC, how do we optimise treatment?

Prof Roberto Iacovelli and Prof Viktor Grünwald

Durable responses in aRCC, how do we optimise treatment? ( Prof Roberto Iacovelli and Prof Viktor Grünwald )

Abemaciclib and fulvestrant show improved efficacy in HR+, HER2- advanced...

Dr Kevin Kalinsky - Winship Cancer Institute, Georgia, USA

Abemaciclib and fulvestrant show improved efficacy in HR+, HER2- advanced breast cancer compared to placebo and fulvestrant ( Dr Kevin Kalinsky - Winship Cancer Institute, Georgia, USA )

Encouraging results using mismatched unrelated donors in stem cell...

Dr Monzr Al Malki and Dr Steven Devine

Encouraging results using mismatched unrelated donors in stem cell transplantation ( Dr Monzr Al Malki and Dr Steven Devine )

ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible...

Prof Xavier Leleu - Poitiers Centre Hospitalier Universitaire, Poitiers, France

ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible patients with newly diagnosed multiple myeloma ( Prof Xavier Leleu - Poitiers Centre Hospitalier Universitaire, Poitiers, France )

More from ecancer